$2.000
-0.058 (-2.91%)收盘时
RGNT 同业对比
In the context of the broader market, RGNT competes directly with industry leaders such as INTS and BNGO. With a market capitalization of $14.05M, it holds a leading position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against INTS's N/A and BNGO's 52.80%. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
Regentis Biomaterials Ltd 财务表现
Regentis Biomaterials has shown a significant turnaround in its financials, with total equity projected to turn positive at $4,744,000 by Q4 2025, compared to negative equity in previous quarters. This indicates improving financial health and potential for growth.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。